Skip to main content

Osmotica Opens Phase 3 Trial On MS Drug

Wilmington-based Osmotica Pharmaceutical has begun recruiting volunteers for a Phase 3 clinical trial to assess the safety and efficacy of its experimental multiple sclerosis drug.

The drug, Arbaclofen Extended Release Tablets, is for MS patients suffering spasticity, the involuntary muscle stiffness or spasms that affect some 80 percent of those with MS.

Praveen Tyle, Ph.D., executve vice president and chief scientific officer, said the trial “marks a critical phase in the history of our company. The need for control of these symptoms and treatment via oral route medication is very critical in the management of patients with multiple sclerosis”

The trial will enroll about 300 people age 18 to 65 into a multicenter randomized double-blind study in the United States and Eastern Europe.


I do not know how to contact anyone to get to be in this clinical study. My cell number is (910) 213-7376. My email address are as follows: Please contact me so that I can sign up for this study.

Add new comment

Refresh Type the characters you see in this picture.
Type the characters you see in the picture; if you can't read them, submit the form and a new image will be generated. Not case sensitive.  Switch to audio verification.